metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	-708 [-1553; 136] /10000 93/256 vs. 112/258	-1157 [-1983; -331] /10000 148/256 vs. 179/258	-
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus pembrolizumab alone
	atezolizumab plus cometinib vs. pembrolizumab alone	1	152 [-583; 888] /10000 45/222 vs. 42/224	450 [-476; 1377] /10000 121/222 vs. 112/224	-
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant